本帖最后由 老马 于 2013-3-13 13:43 编辑
) q4 M8 {! q9 {$ r& E& ~' x" C3 |1 U) K/ L7 d5 F. s
健择（吉西他滨）+顺铂+阿瓦斯汀
9 | W h8 Z G M0 ?+ e6 I5 \- r; w Gemzar +Cisplatin + Avastin
]3 C% d6 K- Q: K6 Z$ F+ dhttp://annonc.oxfordjournals.org/content/21/9/1804.full
) M3 M( R1 N, u. w4 ~$ G+ VOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
+ ^/ f7 s; J( \$ e. FPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 9 J+ x' Q! i% }; \# E* g. C. k
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
7 ]; D, ]8 v, d; y- b3 L$ L
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1002)
0 T2 G& d3 C% A1 ~3 l: e华为网盘附件：4 N/ q4 S- Z2 H8 r5 E
【华为网盘】ava.JPG3 b( ?6 {, i$ a' P8 H
|
肺癌5、8、10年的路线展望---奥西伏
前几天和我一姐姐吃饭聊天，唉，吃着吃着又聊到我俩的共同伤心事了，她妈去年也得
23年脑膜转，目前脑部稳定，肺原发灶
2025.3至2025.5.22脑实质和脑膜稳定，肺部原发灶及胸腔积液控制不住。CEA持续升高。
救命检测免费做！55个癌症家庭的真实
穷到做不起检测是什么滋味？
2023年普通的一天，论坛里突然炸出一句扎心提问："想盲试
3000元的DNA+RNA“双保险”基因检测
“化疗效果不好，靶向药到底能不能用？”
“基因检测太贵，治病的钱还没凑够，先就要
盲试靶向药，第36个月，这一次无效
过完年以后因为工作调用原因，一只没有更新帖子，很多关心我的病友也都发信息问我们最
显身卡
